List of Excipients in Branded Drug UP AND UP MINI NICOTINE POLACRILEX

Generic Drugs Containing UP AND UP MINI NICOTINE POLACRILEX

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Target Corporation	nicotine	11673-881	ACACIA
Target Corporation	nicotine	11673-881	ACESULFAME POTASSIUM
Target Corporation	nicotine	11673-881	CALCIUM POLYCARBOPHIL
Target Corporation	nicotine	11673-881	LIME OIL
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in UP AND UP MINI NICOTINE POLACRILEX?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
1	ACACIA
1	ACESULFAME POTASSIUM
1	CALCIUM POLYCARBOPHIL
1	LIME OIL
># Of NDCs	>Excipient

UP AND UP Mini Nicotine Polacrilex: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 16, 2026

Up & up Mini Nicotine Polacrilex is an over-the-counter nicotine replacement therapy marketed as a mini lozenge. Its commercial position depends less on active-ingredient exclusivity than on low-cost formulation, taste control, dissolution performance, regulatory compliance, retail distribution, and private-label economics. The product is exposed to generic competition because nicotine polacrilex lozenges are regulated under FDA’s OTC nicotine replacement framework and are not dependent on a long-lived, product-specific innovator patent estate.

What is Up & Up Mini Nicotine Polacrilex?

Up & up Mini Nicotine Polacrilex is a nicotine oral lozenge sold under Target’s private-label brand. The product is generally positioned against branded nicotine mini lozenges such as Nicorette Mini Lozenge.

Nicotine polacrilex is a complex of nicotine and a cation-exchange resin. The resin moderates nicotine release in the mouth and supports a solid dosage form suitable for buccal administration. The product is used to reduce withdrawal symptoms during smoking cessation.

Typical marketed strengths are:

Product attribute	Commercial description
Brand	up & up
Active ingredient	Nicotine polacrilex
Dosage form	Mini lozenge
OTC use	Smoking cessation
Common strengths	2 mg and 4 mg nicotine-equivalent strengths
Regulatory category	FDA OTC nicotine replacement therapy
Primary channel	Mass retail, pharmacy, e-commerce, private label
Main competitors	Nicorette, Walgreens, CVS Health, Rite Aid, Walmart private label, Amazon private-label offerings

FDA labeling for nicotine lozenges generally distinguishes between 2 mg and 4 mg strengths based on time to first cigarette and smoking intensity. The lozenge is designed to dissolve slowly in the mouth rather than being chewed or swallowed whole. [1]

What excipients are used in Up & Up Mini Nicotine Polacrilex?

The relevant excipient strategy is built around a compressed or molded oral solid that must control nicotine release, maintain physical integrity, limit moisture sensitivity, and provide acceptable taste.

Public product listings and OTC labeling for nicotine mini lozenges identify excipient classes commonly used in this category, including:

Excipient or excipient class	Formulation role
Mannitol or another polyol	Bulking agent, cooling sensation, reduced hygroscopicity
Sodium alginate or related polymer	Matrix formation and release control
Magnesium stearate	Lubrication during compression
Flavoring agents	Suppression of nicotine bitterness and throat irritation
High-intensity sweeteners	Taste correction without high sugar loading
Acesulfame potassium or sucralose	Sweetness and flavor balance
Ion-exchange resin	Nicotine complexation and release moderation

The exact Up & Up formulation should be treated as a product-specific commercial secret unless confirmed in the current package insert, DailyMed entry, FDA label file, or supplier documentation. Excipient identity alone is unlikely to provide meaningful patent protection because the same materials are widely used in oral nicotine products.

Why mannitol is commercially important

Mannitol is attractive for mini lozenges because it provides bulk at low tablet weight and produces a cooling mouthfeel. It is less hygroscopic than many alternative polyols, which can improve stability in a product containing a moisture-sensitive nicotine-resin complex.

The tradeoff is cost. Mannitol is typically more expensive than some conventional sugar-based fillers. Its commercial value increases when it enables:

Smaller lozenge dimensions
Better mouthfeel
Reduced tablet sticking
Improved packaging stability
Lower moisture pickup
Faster scale-up on existing tablet presses

Why alginate-type polymers matter

A polymeric excipient can control the migration of nicotine from the resin and regulate dissolution in saliva. The target profile is generally a gradual release over several minutes, with sufficient nicotine availability to address craving without creating a sharp bolus.

Polymer selection affects:

Dissolution time
Nicotine release rate
Mouth coating
Tablet hardness
Sensory perception
Batch-to-batch variability

A polymer level that is too high can create a gummy mouthfeel or delay nicotine release. A low level can produce rapid release, poor handling, or excessive throat sensation.

Why flavor and sweetener systems are defensible commercially

Nicotine is bitter and can cause local irritation. Flavor systems therefore have disproportionate commercial importance. A formulation that matches a branded product on nicotine delivery but produces a harsher taste can lose repeat purchasers.

Potential flavor directions include:

Mint and peppermint
Spearmint
Mentholated profiles
Cinnamon
Fruit-mint combinations
Low-intensity neutral profiles

The most valuable flavor system is not necessarily the strongest one. Excessive menthol or mint can increase perceived cooling and irritation. A balanced system can improve adherence during repeated daily dosing.

What patents protect nicotine polacrilex mini lozenges?

Nicotine polacrilex itself is an established active pharmaceutical ingredient and is not a new chemical entity. The core resin complex, nicotine replacement use, and basic lozenge concept have been commercialized for decades.

The principal patent categories historically associated with nicotine lozenges include:

Nicotine-resin complexes
Buccal or oral nicotine delivery
Controlled-release lozenges
Flavor and taste-masking systems
Manufacturing processes
Packaging and moisture-control systems
Regimen or smoking-cessation methods

For Up & Up, the commercial product is more likely to rely on regulatory acceptance, supplier know-how, trade secrets, and cost-efficient manufacturing than on a broad, enforceable patent estate owned by Target.

A patent search should separate:

Patents directed to the nicotine-resin complex
Patents directed to specific lozenge excipient ratios
Patents directed to dissolution or release profiles
Patents directed to branded product attributes
Abandoned, expired, or lapsed patents
Continuations with surviving claims
FDA-listed patents, if any

A generic or private-label nicotine lozenge can often avoid meaningful infringement risk by using a different flavor system, different polymer concentration, alternate manufacturing process, or non-identical dissolution profile.

What is the Orange Book status of Up & Up Mini Nicotine Polacrilex?

Up & Up Mini Nicotine Polacrilex is an OTC product, not an NDA-based prescription drug. The Orange Book is therefore not the primary exclusivity database for this product.

The relevant regulatory pathway is FDA’s OTC nicotine replacement framework, including the requirements in 21 C.F.R. Part 341 and the applicable OTC monograph system. FDA’s nicotine replacement labeling addresses dose selection, administration, warnings, smoking-cessation use, and pregnancy-related precautions. [1][2]

The regulatory consequences are material:

Issue	Up & Up implication
NDA exclusivity	Generally not the core commercial protection
Orange Book listing	Not the principal listing mechanism
Paragraph IV challenge	Generally not the standard pathway for this OTC product
ANDA litigation	Not the ordinary route for an OTC monograph-compliant lozenge
Formulation differentiation	Commercially important despite limited exclusivity
FDA compliance	Labeling, manufacturing, quality, and monograph compliance remain decisive

A product marketed under the OTC monograph system can face rapid competition from other compliant products. The absence of an Orange Book patent strategy does not eliminate all intellectual-property risk, but it shifts the analysis toward patents covering specific formulation or manufacturing claims.

When does Up & Up Mini Nicotine Polacrilex lose exclusivity?

Up & Up does not appear to depend on a conventional prescription-drug exclusivity period. Its market protection is based on private-label branding, Target shelf placement, purchasing scale, supplier relationships, and price positioning.

The product’s effective exclusivity can be lost through:

A competing national-brand price reduction
A lower-cost pharmacy private label
Retailer substitution
E-commerce price transparency
Supplier loss or manufacturing interruption
A reformulated competitor with improved taste
FDA action affecting labeling or manufacturing compliance

The commercial protection period is therefore indefinite in theory but fragile in practice. It is renewed through retailer demand and supply economics rather than through statutory exclusivity.

What formulation patents could create commercial opportunities?

The strongest new patent opportunities are unlikely to cover nicotine polacrilex broadly. They are more likely to cover a narrow combination of composition, performance, and manufacturing parameters.

Taste-masking patents

A patentable taste-masking system could combine:

A defined flavor ratio
A specific sweetener combination
A resin particle-size distribution
A coating or encapsulation layer
A measured reduction in bitterness or throat irritation

The claim must be tied to a technically reproducible formulation. Generic claims covering “a flavoring agent” or “a sweetener” would face substantial validity and prior-art challenges.

Fast-dissolving mini-lozenge patents

A mini lozenge that dissolves within a controlled period while maintaining acceptable hardness could support a differentiated product. Relevant claim elements may include:

Tablet mass
Diameter and thickness
Compression force
Porosity
Polymer level
Dissolution time
Nicotine release at defined intervals

The commercial opportunity is strongest where the dosage form is materially smaller than conventional lozenges but retains equivalent nicotine delivery.

Moisture-protection patents

Nicotine-resin systems and flavored lozenges can be affected by humidity. Patentable approaches may include:

High-barrier blister packaging
Desiccant-integrated cartons
Moisture-resistant coating
Low-water-activity excipient systems
Packaging configurations that reduce flavor loss

Packaging patents can have practical value because they are easier to implement across multiple strengths and flavors.

Low-irritation formulations

A lower-irritation product could support differentiation among consumers who discontinue nicotine replacement because of burning, bitterness, nausea, or throat discomfort.

Potential technical variables include:

Buffer capacity
Resin particle size
Nicotine release rate
Local pH
Menthol concentration
Polymer selection
Saliva-triggered release

Claims should connect the formulation to measurable sensory or pharmacokinetic outcomes.

How strong is the patent estate for Up & Up Mini Nicotine Polacrilex?

The apparent patent strength is low to moderate at the product level and higher at the supplier-process level.

Patent category	Likely strength	Reason
Nicotine polacrilex composition	Low	Long commercial history and extensive prior art
Basic nicotine lozenge	Low	Established dosage-form concept
Generic mint flavor system	Low	Broad prior art and routine formulation practice
Specific release profile	Moderate	Requires validated technical parameters
Specialized taste masking	Moderate to high	Stronger if supported by comparative data
Moisture-barrier packaging	Moderate	Can be valuable if claim scope is narrow and practical
Manufacturing process	Moderate	Trade-secret value may exceed patent value
Retail branding and placement	High commercially, low as patent protection	Distribution advantage rather than patent exclusivity

The main barrier to entry is unlikely to be a blocking patent. It is more likely to be the ability to manufacture a consistent, pleasant-tasting mini lozenge at a retail price that supports Target’s margin requirements.

Which companies are challenging the commercial position?

The competitive landscape includes branded nicotine-replacement manufacturers, pharmacy chains, mass retailers, and contract manufacturers.

Competitor group	Representative companies or brands	Main competitive lever
National brand	Haleon, Nicorette	Brand recognition, clinical familiarity, flavor range
Pharmacy private label	CVS Health, Walgreens, Rite Aid	Store traffic and formulary-style substitution
Mass retail private label	Walmart, Target, Costco	Price and distribution
E-commerce sellers	Amazon and third-party sellers	Search visibility and price competition
Contract manufacturers	OTC pharmaceutical manufacturers	Scale, regulatory systems, formulation replication
Alternative NRT	Patches, gum, inhalers, sprays	Convenience and dosing flexibility

The largest threat is not necessarily a direct patent challenge. It is shelf-level substitution by a lower-priced equivalent product with comparable labeling and acceptable taste.

What generic launch risks exist for nicotine mini lozenges?

Generic and private-label launch risk is high because:

The active ingredient is established.
The dosage form is familiar.
OTC demand is persistent.
Product development cycles are shorter than for prescription medicines.
Manufacturing can be outsourced.
Consumers are often willing to substitute based on price.

The main launch risks are technical and regulatory:

Dose uniformity: Nicotine content must remain within specification across the batch.
Dissolution control: Release must be consistent across strengths and lots.
Taste performance: Bitterness and irritation can reduce adherence.
Moisture stability: Packaging and excipients must protect shelf life.
Label compliance: Directions, warnings, strength selection, and age restrictions must remain accurate.
Child safety: Nicotine toxicity creates heightened packaging and handling requirements.
Supply continuity: Resin, flavor, and specialized packaging suppliers can become bottlenecks.

What manufacturing and IP barriers affect the product?

The most important manufacturing barriers are process control and nicotine handling.

Resin loading and blending

Nicotine polacrilex requires controlled blending to achieve uniform active distribution. Variability in resin particle size, moisture, and nicotine loading can affect potency and dissolution.

Compression and tablet integrity

Mini lozenges provide limited material for achieving hardness, friability control, and slow dissolution. Compression settings must avoid:

Capping
Cracking
Sticking
Excessively slow dissolution
Rapid dose dumping

Flavor retention

Volatile flavor compounds can migrate or evaporate during processing and storage. Flavor loss can reduce consumer acceptance even when the product remains within chemical specifications.

Packaging

Blister packaging is commercially attractive because it supports unit-dose protection and child-safety handling. Bottles may reduce cost but can create greater exposure to humidity and repeated opening.

Trade secrets

The highest-value know-how may include:

Resin preconditioning
Mixing sequence
Lubrication time
Compression force
Flavor addition method
Moisture limits
Packaging-line controls
Stability acceptance criteria

These factors can be protected as trade secrets even when the final excipient list is publicly visible.

What licensing deals could support the product?

A licensing strategy could target four areas:

Licensing target	Commercial purpose
Nicotine-resin supplier	Secure active-quality consistency and supply
Taste-masking technology	Improve tolerability and brand differentiation
Controlled-release polymer platform	Establish a measurable release advantage
Moisture-barrier packaging	Extend shelf life and reduce flavor degradation

A formulation license is most valuable when it provides a documented advantage in consumer acceptability, dissolution, stability, or manufacturing yield. A license covering only standard excipients is unlikely to justify a meaningful royalty.

Target’s private-label model also creates an opportunity for contract manufacturers to offer platform products that can be adapted for multiple retailers. The same manufacturing platform could support nicotine lozenges, caffeine lozenges, oral electrolyte tablets, and other small-format OTC products.

What are the main commercial opportunities?

Private-label cost leadership

The clearest opportunity is a low-cost equivalent positioned below Nicorette and other national brands. Margin depends on procurement, tablet yield, packaging cost, and retailer volume.

Premium mini-lozenge

A smaller, smoother, lower-irritation product could support a modest premium if it improves repeat use. The premium must be supported by consumer-perceivable differences because nicotine replacement products are highly price-sensitive.

Flavor expansion

Flavors can create incremental sales and reduce dependence on a single mint SKU. The most practical portfolio strategy is to retain a core mint product and test differentiated profiles with limited inventory exposure.

Dual-strength architecture

Offering 2 mg and 4 mg strengths allows alignment with FDA labeling and consumer smoking intensity. A common platform with strength-specific resin loading can reduce development and manufacturing costs.

E-commerce multipacks

Large-count packs, subscription options, and multi-pack configurations can improve unit economics while reducing packaging cost per lozenge. E-commerce also allows search-based targeting of consumers seeking nicotine gum alternatives.

International expansion

Geographic expansion requires separate review of nicotine dose limits, excipient acceptability, packaging rules, smoking-cessation claims, and product classification. A U.S. OTC-compliant formula may require changes in Canada, the European Union, the United Kingdom, Australia, or other markets.

How does Up & Up compare with Nicorette Mini Lozenge?

Attribute	Up & Up Mini Nicotine Polacrilex	Nicorette Mini Lozenge
Ownership model	Retailer private label	National brand
Primary advantage	Price and Target distribution	Brand recognition and consumer trust
Patent dependence	Likely limited	Historical branded formulation and delivery IP may be broader
Formulation transparency	Label-dependent	More extensive branded product documentation
Consumer acquisition	Retail shelf and Target digital ecosystem	Pharmacy, advertising, cessation familiarity
Switching risk	High if price gap narrows	Lower among brand-loyal consumers
Innovation opportunity	Taste, format, pack size, price	Line extensions and clinical positioning

The competitive outcome is likely determined by perceived equivalence. If consumers view the Up & Up product as interchangeable with Nicorette, price and availability dominate. If the branded product has better taste or smoother dissolution, it can retain a premium.

What FDA and legal issues should investors monitor?

The key FDA issues are OTC monograph compliance, manufacturing quality, labeling accuracy, adverse-event reporting, and nicotine-specific packaging and safety requirements. FDA’s Center for Drug Evaluation and Research regulates nicotine replacement products as drug products even when they are sold without a prescription. [2]

Legal monitoring should focus on:

Current FDA monograph requirements
Product-specific FDA enforcement actions
Trademark disputes involving retailer branding
Supplier warranties and indemnities
Formulation and packaging patent claims
Trade-secret protections
Product-liability exposure from nicotine ingestion
Changes to child-resistant packaging expectations
Retailer and manufacturer responsibilities

Paragraph IV litigation is not the expected central risk for an OTC monograph product. A patent dispute would more likely involve a specific formulation, manufacturing process, packaging configuration, or branded trade dress.

Key Takeaways

Up & Up Mini Nicotine Polacrilex is primarily a private-label OTC nicotine replacement product.
Its commercial protection comes from Target distribution, price, and supply economics rather than a conventional prescription-drug exclusivity period.
The core nicotine polacrilex and mini-lozenge concepts have extensive prior art and limited broad patentability.
The strongest new IP opportunities involve taste masking, low-irritation delivery, controlled dissolution, moisture protection, and manufacturing processes.
Mannitol, alginate-type polymers, lubricants, sweeteners, and flavor systems are central to product performance.
The principal competitive threat is retailer substitution by another low-cost, compliant nicotine lozenge.
Manufacturing consistency, flavor retention, packaging, and nicotine-dose uniformity are more important entry barriers than a broad blocking patent.
A platform formulation could support multiple strengths, flavors, pack sizes, and retailer customers.

FAQs

Does Up & Up Mini Nicotine Polacrilex have FDA approval?

It is marketed as an OTC nicotine replacement product under the FDA regulatory framework for nicotine lozenges. The applicable compliance basis is the OTC monograph and associated FDA requirements rather than necessarily an individual prescription-style NDA approval.

Is nicotine polacrilex protected by an active patent?

The active ingredient has been commercially used for many years. Broad composition and dosage-form claims face substantial prior-art exposure. Narrow patents covering specific release, taste-masking, packaging, or manufacturing features may remain relevant.

Can a competitor copy the excipients in Up & Up nicotine lozenges?

A competitor can generally use the same common excipient classes, subject to regulatory and quality requirements. Copying a specific patented composition, manufacturing process, trade dress, or protected supplier technology could create legal exposure.

Which excipient has the greatest impact on nicotine release?

The nicotine-resin complex controls the fundamental release behavior, while polymer type and concentration can materially alter dissolution and mouthfeel. Particle size, compression force, and tablet porosity also affect release.

Is a nicotine mini lozenge suitable for international licensing?

Yes, but each market requires separate assessment of nicotine classification, allowable dose, excipient status, labeling, packaging, cessation claims, and manufacturing requirements. The U.S. OTC formulation should not be assumed to transfer without modification.

References

U.S. Food and Drug Administration. (2022). Nicotine replacement therapy labeling and smoking cessation products. https://www.fda.gov
Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. https://www.ecfr.gov
U.S. Food and Drug Administration. (2024). Drug products marketed under the OTC monograph system. https://www.fda.gov
U.S. Food and Drug Administration. (2024). DailyMed: Nicotine polacrilex lozenge labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
U.S. Patent and Trademark Office. (2024). Patent Public Search. https://ppubs.uspto.gov/patents/
National Library of Medicine. (2024). DailyMed drug labeling database. https://dailymed.nlm.nih.gov

More… ↓

⤷ Start Trial